L.E.K. Consulting on Biopharma 2026: The Year Discovery Has to Prove It Can Scale
For most of the past decade, biopharma rewarded the boldest science. A convincing mechanism, a first-in-class target, a compelling early readout — that was often enough to raise the next round. L.E.K. Consulting's outlook for 2026 describes a different market: one where the burden of proof has moved downstream, to manufacturing cost, commercial pathway, and demonstrated value to the patient and the payer.
The analysis below draws on projections from L.E.K. Consulting, with research led by Simon Middleton, Partner and Head of Europe Life Sciences. Five forces stand out.
1. AI stops being a pilot and becomes the operating layer of R&D
Artificial intelligence has left the phase where it lived in a separate innovation team with its own budget. Companies are now folding it into the core: generative design of candidate molecules, target identification pulled out of large-scale genomic datasets, and adaptive trial designs that compress timelines from years into months. The shift is less about a single breakthrough model than about who has the data infrastructure to use one. We traced the same trend in AI and the Life Sciences Industry.
2. Advanced therapies face a manufacturing reckoning
Cell therapy, gene therapy, mRNA and protein degraders have cleared the scientific bar. The open question is economic. Attention has shifted decisively to cost of goods sold, cold-chain reliability, and whether a process that works for fifty patients holds up for five thousand. In this cycle, a therapy that works but cannot be produced affordably is a research success and a commercial failure.
3. Cardiometabolic franchises expand well beyond obesity
The incretin and GLP-1 class has become the defining commercial story of the decade, and its indications keep widening — heart failure, chronic kidney disease, metabolic liver disease (MASH), sleep apnoea. Each expansion requires large, expensive outcome trials, which concentrates the field around companies that can fund them. The result is a franchise dynamic more familiar from consumer markets than from traditional pharma.
4. Digital tools and real-world evidence enter the pricing conversation
Standalone health apps have largely given way to digital ecosystems built around a specific therapy. Remote monitoring and digital biomarkers generate evidence from ordinary clinical practice rather than the controlled conditions of a trial — and that evidence increasingly carries weight when a company negotiates reimbursement with insurers and regulators. Proving a drug works is no longer separable from proving it works in the field.
5. Capital discipline reshapes M&A
Investors have tightened considerably. Acquisition and licensing activity is concentrating on validated multi-asset platforms and late-stage candidates with a visible route to market, rather than early-stage bets on novel biology. Risk has not disappeared from the sector; it has been repriced.
The strategic shift in one table
| Focus area | Traditional model | New paradigm (2026) |
|---|---|---|
| AI adoption | Siloed pilots in isolated teams | Integrated end-to-end R&D platform |
| Advanced modalities | Exploring biological feasibility | Manufacturing scalability & COGS efficiency |
| Cardiometabolic drugs | Single focus on diabetes and obesity | Expansion into systemic indications & comorbidities |
| Digital approach | Separate companion mobile apps | Sensors and RWE integrated with the therapy |
| Investment & M&A | Speculative high-risk early-stage assets | Measured ROI discipline & late-stage assets |
What it means for science-based founders
For research ecosystems in emerging markets, including Indonesia, this changes what a credible pitch looks like. A laboratory result paired with a vague plan to "find a manufacturing partner later" now reads as an unpriced risk. The teams that raise capital are the ones that can already answer how the product gets made, at what unit cost, and who pays for it — questions we examined in The Future of Biofinancing.